[Control of an epidemic of meningococcal meningitis in Central Africa]. 1996

M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
Mission Bioforce, Institut de médecine tropicale du Service de santé des Armées, Le Pharo, Marseille Armées, France.

A severe epidemic of group A meningococcal disease occurred in the northwest part of the Central African Republic from January to March 1992. The outbreak affected a large and densely populated area, with a poor road network, located 400 kilometers south of the classical meningitis belt. An initial selective vaccination campaign was carried out by the national health care service. As the epidemic was continuing, the national authorities asked for international assistance. The French participated by sending Bioforce, a medical task force designed by the Ministry of Defense, with the financial support of the Ministry of Cooperation. Neisseria meningitidis strains were isolated and identified within 36 hours by the Bioforce field laboratory. Strains from 24 patients were sent to the Pasteur Institute in Paris (Neisseria Unit) for serotyping, testing of antibiotic susceptibility, and multilocus enzyme electrophoresis. With one exception, all strains had formula A:4:P1.9. By an initial rapid assessment, the limits of the affected area and populations were determined. The weekly incidence rates observed in different areas varied within a range of 3 to 10 cases per 1,000, with fatality rates from 20 to 30 cases per 100. The spread of the epidemic was stopped by a mass vaccination campaign, which targeted the entire population (200,000 immunizations) of the affected area. The case fatality rate could not be reduced below 15%, despite antimicrobial treatments implemented as soon as possible. The optimal treatment was the standard single intramuscular injection of oily chloramphenicol. The predictive values of clinical symptoms were calculated. The efficacy of vaccination was estimated by comparison of the percentage of people immunized and the proportion of those vaccinated people who developed meningitis identified during the 3 weeks following the mass vaccination campaign. The efficacy varied between 93 to 95% according to the place. The typical weekly incidence rate of 1 case per 1,000 is not a relevant threshold to sufficiently and immediately detect a meningitis outbreak and needs to be reconsidered.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D011159 Population Surveillance Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy. Surveillance, Population
D002488 Central African Republic A republic in central Africa south of CHAD and SUDAN, north of DEMOCRATIC REPUBLIC OF THE CONGO, and east of CAMEROON. The capital is Bangui. Ubangi-Shari
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002701 Chloramphenicol An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
January 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
February 2017, Pathogens and global health,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
March 1993, The Medical journal of Australia,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
August 1970, Military medicine,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
January 1996, Medecine tropicale : revue du Corps de sante colonial,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
November 1991, The Medical journal of Australia,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
June 2005, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
July 1981, Lancet (London, England),
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
March 1987, International journal of epidemiology,
M Merlin, and G Martet, and J M Debonne, and P Nicolas, and C Bailly, and D Yazipo, and J Bougère, and A Todesco, and R Laroche
September 1975, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!